Heart Attack Clinical Trials

Find Heart Attack Clinical Trials Near You

Comparison of Outcomes of Chronic Limb Threatening Ischemia in Diabetic and Hypertensive Patients With Hypercholesterolemia: Aspirin Alone Versus Low-Dose Rivaroxaban Plus Aspirin, in Mayo Hospital, Lahore

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Early Phase 1
SUMMARY

The goal of this \*\*clinical trial\*\* is to compare the effectiveness of \*\*low-dose rivaroxaban plus aspirin versus aspirin alone\*\* in patients aged 40-70 years with \*\*chronic limb-threatening ischemia, diabetes mellitus, hypertension, and hypercholesterolemia\*\*. The main questions it aims to answer are: * Does low-dose rivaroxaban plus aspirin reduce \*\*major adverse limb events (MALE)\*\*, such as acute limb ischemia and amputation? * Does the combination therapy reduce \*\*major adverse cardiovascular events (MACE)\*\*, such as myocardial infarction and stroke, and improve limb-related outcomes? Researchers will compare \*\*low-dose rivaroxaban (2.5 mg twice daily) plus aspirin (75-100 mg daily)\*\* with \*\*aspirin alone\*\* to see if combination therapy provides better outcomes over a period of \*\*6 months\*\*. Participants will: * Undergo baseline clinical assessment, blood tests, ABPI/TBI, and Doppler/duplex assessment. * Be randomly assigned to either the rivaroxaban plus aspirin group or the aspirin-alone group. * Attend follow-up visits at specified intervals for assessment of \*\*WIFI score, ABPI, wound healing, MALE, MACE, and quality of life\*\*. * Be assessed for treatment compliance, side effects, and bleeding during follow-up.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 40
Maximum Age: 70
Healthy Volunteers: f
View:

• All patients of CLTI managed conservatively

• ASA score of 3 or more

• Age 40-70 yrs

• Diagnosed case of Diabetes mellitus type 2 (HbA1c \>8)

• Blood Pressue ( \>130/90 , \<180/100 )

• Hypercholestrolemia (Total cholesterol ≥200 mg/dL )

• ABPI \< 0.6

• Claudication distance \< 100 meters

• Provided written informed consent (for prospective or interventional studies)

Locations
Other Locations
Pakistan
Mayo Hospital Lahore
RECRUITING
Lahore
Contact Information
Primary
Hafsa Farooq, MBBS
hafsafarooqiqbal.99@gmail.com
+923335700188
Time Frame
Start Date: 2026-06-01
Estimated Completion Date: 2027-04-01
Participants
Target number of participants: 78
Treatments
Active_comparator: Aspirin
Active_comparator: Low-Dose Rivaroxaban and Aspirin,
Low dose Rivaroxaban 2.5 mg used orally twice a day in combination with Aspirin is a vascular protective dose as described in COMPASS and VOYEGAR PAD trials. This low dose has antithrombotic effect without full anticoagulation ,thus less bleeding risk compared to standard anticoagulant dose.
Sponsors
Leads: King Edward Medical University

This content was sourced from clinicaltrials.gov